Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Anesiva launches needle-free system to reduce pain from IV starts and blood draws in children

Anesiva : 01 July, 2008  (New Product)
Anesiva has launched Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system, which is an easy-to-administer, single-use, needle-free system that reduces the pain associated with peripheral intravenous (IV) line placements and blood draws in children three to 18 years of age.
Zingo works quickly, within one to three minutes, to relieve pain at the needle insertion site.

'Zingo is the first easy-to-administer, fast-acting local anaesthetic that could lead to a paradigm shift in the approach to venous access procedures such as drawing blood and placing IV lines in children,' said William T Zempsky, MD, associate professor, Department of Pediatrics, University of Connecticut; associate director, Pain Relief Program, Connecticut Children's Medical Center, Hartford, who led the paediatric trials of Zingo. 'Because available topical anaesthetic creams can take up to 30 to 60 minutes to work, healthcare providers have had to sacrifice patient comfort when performing the numerous peripheral venous access procedures that occur each day. Zingo will be a source of relief to both them and the children and parents they deal with every day.'
'The commercial launch of Zingo is a major milestone that is notable both for our company and for patients. We are fully committed to driving successful market introduction for this exciting new product,' said Michael L Kranda, Anesiva's president and chief executive officer.

'We are initially focusing our efforts on the children's hospitals and academic medical centres with large paediatric units which facilitate the majority of acute and chronic pediatric care. Many of the patients served in these hospitals undergo peripheral venous access procedures repeatedly, and are undertreated, indicating a significant unmet medical need,' said Nancy E Donahue, senior vice president, sales and marketing. Anesiva estimates that approximately 18 million paediatric peripheral venous access procedures are performed annually in US hospitals.

Anesiva and its co-promotion partner Sagent Pharmaceuticals are working in tandem to educate caregivers about the importance of addressing peripheral venous access pain in children, and to ensure Zingo availability through hospital pharmacies. Anesiva's team of 15 hospital-based regional account managers with an average of 14 years' industry experience, led by two directors who have a combined 30 years' experience, will drive the launch of this product in the USA. Sagent has assigned 15 field representatives, all of whom have an average of more than 18 years' hospital selling experience and whose national account representatives have an average of 25 years of hospital sales experience.

Zingo is currently manufactured with established, approved processes. Anesiva continues to pursue Zingo manufacturing scale-up in order to reduce cost of goods and meet anticipated increasing market demand.

Anesiva intends to grow a global brand for Zingo through geographically based license and distribution agreements with companies that have expertise in hospital-based markets in their territories, and has already entered into agreements for several major markets.

Sigma Tau will market Zingo in most major European markets; Medical Futures is responsible for commercialising Zingo in Canada; and Green Vision will commercialise Zingo in several countries in the Middle East. Planning for local regulatory filings for marketing approval is underway. Discussions for license and distribution agreements in other major markets are in progress. Anesiva also has established a joint venture in China for the assembly of Zingo devices using US-sourced components.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo